Sanofi’s Admelog is the first meal-time insulin copy the FDA has approved.
Precision Medicine: A simple test aims to predict which treatment for cystic fibrosis is most likely to work for each patient.
Drugs reviewed by the FDA in programs intended to speed drug development were approved nearly a year quicker than drugs reviewed through normal processes.
Applying an FDA-approved nutrition source called Intralipid before nano-drug chemotherapy can reduce the amount of the toxic drugs that settle in the body.
Celgene, a company with a market cap of $80 billion and expectations to grow sales by 14.5% annually through 2020 might be the answer to Pfizer’s woes.
As the year draws to a close, Rick Duprey, writing for The Motley Fool, takes a look back at three biotechs that have quadrupled this year.
With 2017 coming to a close, the biopharma industry and the US Food and Drug Administration (FDA) are preparing to face a very busy time.
The final chapter in an unfortunate saga in MS research appears to have been written by the scientist who started the affair in the first place.
Novartis has revealed plans to potentially snatch some patients from GlaxoSmithKline with Advair rival Ultibro Breezhaler.
Exposure to antibiotics in mothers may increase risk for inflammatory bowel diseases in their offspring, according to new research.
Last month, Tristan Roberts became the first human to inject himself with an untested, experimental gene therapy, live on Facebook.
If you have been keeping tabs on the website this week, then you’ll be aware at just how much of a booming year biotech companies are having.